PhD Scientific Days 2023

Clinical Medicine - Posters J

SARS-CoV2 Vaccination In Hungarian IPF Patients

Előadó neve

Dr. Tóth, Nóra Melinda

Neptun code

ALV8KB

Előadó munkahelye

Department of Pulmonology, Semmelweis University

Előadó telefonszáma

06206663433

Előadó e-mail címe

tnora96@gmail.com

Az előadás címe

SARS-CoV2 Vaccination In Hungarian IPF Patients

Szerző(k) neve és munkahelye

Nóra Melinda Tóth1, Tamás Nagy1, Enikő Bárczi1, Alexandra Nagy1, Noémi Eszes1, Krisztina Vincze1, Anikó Bohács1, Veronika Müller1

1 Department of Pulmonology, Semmelweis University, Budapest

Bemutatás módja

Poszter

Szekció

Clinical Medicine - Posters J

Language of the presentation

English

Preferred session

Clinical Medicine

Összefoglaló szövege

Introduction: SARS-CoV2 infection is associated with significant risk of coronavirus disease (COVID-19) and represents a significant risk factor for functional deterioration in idiopathic pulmonary fibrosis (IPF) patients.

Methods: We retrospectively reviewed all IPF patients treated at our university center for their SARS-CoV2 vaccination status starting from January 2021.

Results: Total of 69 (out of treated 73 IPF patients) received minimum 2 doses of SARS-CoV2 vaccines (male 56.52%, age: 71.22 ± 9.65 years), 21 of them were vaccinated with non-mRNA vaccines (BBIBP-CorV-Sinopharm, ChAdOx1-AstraZeneca, Gam-Covid-Vac-Sputnik and Ad26.COV2.S-Janssen), while 48 mRNA vaccines. Most patients received BNT162b2-mRNA-Pfizer/Biontech (57.97%), followed by BBIBP-CorV-Sinopharm (15.94%) and mRNA-1273-Moderna (11.59%). Majority (N=57) of patients also took a third dose, mostly mRNA type (N=55), only 2 of them received a non-mRNA booster (Janssen). From all patients there was a total of 1 case of hospitalization and death due to COVID-19 pneumonia. This patient was vaccinated, but received no booster dose and more than 6 months passed between the vaccination and the COVID infection; she also received immunosupressive treatment at the time of the infection. No significant adverse event related to the vaccinations was reported in any patients. IPF patients were mainly in a good functional state (FVC = 2.2 [1.74-3.11] L; 78.24 ± 22.66%) with reduced diffusion capacity (TLCO = 4.56 [3.42-6.16] mmol/kPa/min; 61.23 ± 21.42%).

Conclusion: SARS-CoV2 vaccination is utmost important in IPF patients, and independent of vaccine type used it resulted in significantly decreased risk of COVID-19 hospitalization.

University and Doctoral School

Semmelweis University, Károly Rácz Doctoral School of Clinical Medicine

Supervisor

Veronika Müller

Publication of my abstract

I give consent to the publication of my abstract on the website of the congress.

Kind

Szabad

Status

elfogadva

Accepted presentation method

poszter

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

6871

Start

11:06

End

11:11

Authors (legacy)

Nóra Melinda Tóth1, Tamás Nagy1, Enikő Bárczi1, Alexandra Nagy1, Noémi Eszes1, Krisztina Vincze1, Anikó Bohács1, Veronika Müller1

1 Department of Pulmonology, Semmelweis University, Budapest